2. Kurebayashi J, Otsuki T, Tang CK, Kurosumi M, Yamamoto S, Tanaka K, Et Al. Isolation

Supplementary Table S1. TP53 mutation profiles of human breast cancer cells and HCT116 colon cancer cells

Name Pos. WT Mut AA MutAA NB WAF1 SUM149 237 ATG ATA Met Ile 123 0.43 MDA-MB-231 280 AGA AAA Arg Lys 78 0.46 MDA-MB-468 273 CGT CAT Arg His 780 1.01 SUM159 158 CGC ins3a Arg InF 1 NA SUM190 317 CAG TAG Gln Stop 25 NA BT-549 249 AGG AGC Arg Ser 34 12.42 HCC70 248 CGG CAG Arg Gln 883 0 T47D 194 CTT TTT Leu Phe 28 14.38 KPL-4 (1, 2) WT MCF-7 WT ZR75-1 WT HCT116 (3) WT HCT116p53-/- (3) p53-/- TP 53 mutation profiles were referred from Handbook of p53 mutation in cell lines (http://p53.free.fr) unless mentioned otherwise. Abbreviations: Pos., codon position (1 to 393); WT, normal base sequence of the codon in which the mutation occurred; Mut, sequence of the mutated codon; ins3a, insertion of 3 bases; AA, wild-type amino acid; MutAA, mutant amino acid; Stop; nonsense mutation; InF, inframe insertion; NB, number of tumors with this particular mutant in the database; WAF1, residual transcriptional activity of mutant p53 on the WAF1 promoter (% compared with wild-type p53). Each p53 mutation listed is a single mutation but not double or more in each cell line.

References 1. Li C, Lee B, Woodward WA, Ueno NT, Robertson F, Reube J, et al. p53 Mutation in

Inflammatory Breast Cancer Cell Lines. Thirty-Second Annual CTRC‐AACR San Antonio Breast Cancer

Symposium‐‐ Dec 10‐13, 2009; San Antonio, TX. 2009.

2. Kurebayashi J, Otsuki T, Tang CK, Kurosumi M, Yamamoto S, Tanaka K, et al. Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6. Br J Cancer. 1999;79:707-17. 3. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 1998;282:1497-501.